Thomas J. Dilling

Thomas J. Dilling

Auto-generated profile, based on publicly available information

Thomas J. Dilling

Department of Radiation Oncology, H Lee Moffitt Cancer Center, Tampa, FL, United States

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2011 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
GZGeoffrey G Zhang
Geoffrey G Zhang
LKLichung Ku
Lichung Ku
TDThomas J Dilling
Thomas J Dilling
CSCraig W Stevens
Craig W Stevens
RZRay R Zhang
Ray R Zhang
VFVladimir Feygelman
Vladimir Feygelman
Frequently, three-dimensional (3D) conformal beams are used in lung cancer stereotactic body radiotherapy (SBRT). Recently, volumetric modulated arc therapy (VMAT) was introduced as a new treatment modality. VMAT techniques shorten delivery time, reducing the possibility of intrafraction target motion. However dose distributions can be quite different from standard 3D therapy. This study quantifies those differences, with focus on VMAT plans using unflattened photon beams. A total of 15 lung cancer patients previously treated with 3D or VMAT SBRT were randomly selected. For each patient, non-coplanar 3D, coplanar and non-coplanar VMAT and flattening filter free VMAT (FFF-VMAT) plans were generated to meet the same objectives with 50 Gy covering 95% of the PTV. Two dynamic arcs were used in each VMAT plan. The couch was set at ± 5° to the 0° straight position for the two non-coplanar arcs. Pinnacle version 9.0 (Philips Radiation Oncology, Fitchburg WI) treatment planning system with VMAT capabilities was used. We analyzed the conformity index (CI), which is the ratio of the total volume receiving at least the prescription dose to the target volume receiving at least the prescription dose; the conformity number (CN) which is the ratio of the target coverage to CI; and the gradient index (GI) which is the ratio of the volume of 50% of the prescription isodose to the volume of the prescription isodose; as well as the V20, V5, and mean lung dose (MLD). Paired non-parametric analysis of variance tests with post-tests were performed to examine the statistical significance of the differences of the dosimetric indices. Dosimetric indices CI, CN and MLD all show statistically significant improvement for all studied VMAT techniques compared with 3D plans (p < 0.05). V5 and V20 show statistically significant improvement for the FFF-VMAT plans compared with 3D (p < 0.001). GI is improved for the FFF-VMAT and the non-coplanar VMAT plans (p < 0.01 and p < 0.05 respectively) while the coplanar VMAT plans do not show significant difference compared to 3D plans. Dose to the target is typically more homogeneous in FFF-VMAT plans. FFF-VMAT plans require more monitor units than 3D or non-coplanar VMAT ones. Besides the advantage of faster delivery times, VMAT plans demonstrated better conformity to target, sharper dose fall-off in normal tissues and lower dose to normal lung than the 3D plans for lung SBRT. More monitor units are often required for FFF-VMAT plans.

1 July 2015 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KAKamran A. Ahmed
Kamran A. Ahmed
WFWilliam J. Fulp
William J. Fulp
ABAnders Berglund
Anders Berglund
SHSarah E. Hoffe
Sarah E. Hoffe
TDThomas J. Dilling
Thomas J. Dilling
JTJavier F. Torres-Roca
Javier F. Torres-Roca

25 September 2017 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
QLQian Li
Qian Li
JKJongphil Kim
Jongphil Kim
YBYoganand Balagurunathan
Yoganand Balagurunathan
JQJin Qi
Jin Qi
YLYing Liu
Ying Liu
TDThomas J. Dilling
Thomas J. Dilling
Background Predicting recurrence after stereotactic body radiotherapy (SBRT) in non-small cell lung cancer (NSCLC) patients is problematic, but critical for the decision of following treatment. This study aims to investigate the association of imaging features derived from the first follow-up computed tomography (CT) on lung cancer patient outcomes following SBRT, and identify patients at high risk of recurrence. Methods Fifty nine biopsy-proven non-small cell lung cancer patients were qualified for this study. The first follow-up CTs were performed about 3 months after SBRT (median time: 91 days). Imaging features included 34 manually scored radiological features (semantics) describing the lesion, lung and thorax and 219 quantitative imaging features (radiomics) extracted automatically after delineation of the lesion. Cox proportional hazard models and Harrel’s C-index were used to explore predictors of overall survival (OS), recurrence-free survival (RFS), and loco-regional recurrence-free survival (LR-RFS). Five-fold cross validation was performed on the final prognostic model. Results The median follow-up time was 42 months. The model for OS contained Eastern Cooperative Oncology Group (ECOG) performance status (HR = 3.13, 95% CI: 1.17–8.41), vascular involvement (HR = 3.21, 95% CI: 1.29–8.03), lymphadenopathy (HR = 3.59, 95% CI: 1.58–8.16) and the 1st principle component of radiomic features (HR = 1.24, 95% CI: 1.02–1.51). The model for RFS contained vascular involvement (HR = 3.06, 95% CI: 1.40–6.70), vessel attachment (HR = 3.46, 95% CI: 1.65–7.25), pleural retraction (HR = 3.24, 95% CI: 1.41–7.42), lymphadenopathy (HR = 6.41, 95% CI: 2.58–15.90) and relative enhancement (HR = 1.40, 95% CI: 1.00–1.96). The model for LR-RFS contained vascular involvement (HR = 4.96, 95% CI: 2.23–11.03), lymphadenopathy (HR = 2.64, 95% CI: 1.19–5.82), circularity (F13, HR = 1.60, 95% CI: 1.10–2.32) and 3D Laws feature (F92, HR = 1.96, 95% CI: 1.35–2.83). Five-fold cross-validated the areas under the receiver operating characteristic curves (AUC) of these three models were all above 0.8. Conclusions Our analysis reveals disease progression could be prognosticated as early as 3 months after SBRT using CT imaging features, and these features would be helpful in clinical decision-making.

1 August 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
KAKamran A. Ahmed
Kamran A. Ahmed
JSJacob G. Scott
Jacob G. Scott
JAJohn A. Arrington
John A. Arrington
ANArash O. Naghavi
Arash O. Naghavi
GGG. Daniel Grass
G. Daniel Grass
JTJavier F. Torres-Roca
Javier F. Torres-Roca

29 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DNDipesh Niraula
Dipesh Niraula
KCKyle Cuneo
Kyle Cuneo
IDIvo D. Dinov
Ivo D. Dinov
BGBrian D. Gonzalez
Brian D. Gonzalez
JJJamalina B. Jamaluddin
Jamalina B. Jamaluddin
Issam El NaqaIssam El Naqa
Issam El Naqa
AI decision support systems can assist clinicians in planning adaptive treatment strategies that can dynamically react to individuals’ cancer progression for effective personalized care. However, AI’s imperfections can lead to suboptimal therapeutics if clinicians over or under rely on AI. To investigate such collaborative decision-making process, we conducted a Human–AI interaction study on response-adaptive radiotherapy for non-small cell lung cancer and hepatocellular carcinoma. We investigated two levels of collaborative behavior: model-agnostic and model-specific; and found that Human–AI interaction is multifactorial and depends on the complex interrelationship between prior knowledge and preferences, patient’s state, disease site, treatment modality, model transparency, and AI’s learned behavior and biases. In summary, some clinicians may disregard AI recommendations due to skepticism; others will critically analyze AI recommendations on a case-by-case basis; clinicians will adjust their decisions if they find AI recommendations beneficial to patients; and clinician will disregard AI recommendations if deemed harmful or suboptimal and seek alternatives.

1 November 2011 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
TDThomas J. Dilling
Thomas J. Dilling
KBKyounghwa Bae
Kyounghwa Bae
RPRebecca Paulus
Rebecca Paulus
DWDeborah Watkins-Bruner
Deborah Watkins-Bruner
AGAdam S. Garden
Adam S. Garden
BMBenjamin Movsas
Benjamin Movsas